Navamedic (NAVA)

[Dnalege]

Hva skjedde her? Kanskje noen som plutselig skjønte at dette må være et kupp…

[ffelicis]

Vet noen om de kliniske studiene på navamedics produkter ligger tilgjengelig noe sted? mulig jeg er dårlig på å lete☺️

[TekBot]

Transaction by primary insider’s close associate

Ingerø Reiten Investment Company AS has pledged 3 563 042 Navamedic ASA shares in favour of DnB in connection with a new loan facility.
…

Vis børsmeldingen

Kilde

[Quadruple]

Kliniske studier? Da snakker du reseptbelagte legemidler. Hva tenker du på?

[Asker]

NAVA selger andres produkter, de har ikke utviklet noe av de de selger selv nå. Produktet som startet selskapet ble en flopp, men de klarte faktisk å selge det videre.

[ffelicis]

ok ,takk, var bare i tankegangen på å sammenligne effekten av f.eks Cysticina med andre reseptbelagte midler mot samme lidelse. Men forstod det som at nava var utvikler også…

[Asker]

Ja, det er jo interessant selvfølgelig. Stor fordel at dette er reseptfritt.

– Urinveisinfeksjon er et plagsomt og ofte gjentakende problem for kvinner. Vi vet også at mange kvinner behandler plagene selv. Til nå har det dessverre vært få, gode reseptfrie alternativer i apotek for lindring av symptomene, og vi er derfor glade for at Cysticina® nå blir tilgjengelig i Norge, sier Kathrine Gamborg Andreassen, CEO Navamedic.

Cysticina ® er Norges første reseptfrie legemiddel av sitt slag, og er nå tilgjengelig på apotek.

[TekBot]

Navamedic ASA: Enters long term distribution agreement for PrecisionBiotics Zenflore® in the Nordics with Novozymes.

Oslo, April 8, 2021 - Navamedic ASA (OSE: NAVA) enters exclusive long term
distribution agreement with Novozymes for PrecisionBiotics Zenflore® in the
Nordics. Through this agreement Navamedic strengthens its position within
…

Vis børsmeldingen

consumer healthcare and clinically proven probiotics for specific disease areas.

“We are proud to announce the agreement with Novozymes which expands our product
portfolio within probiotics for specific disease areas in the Nordics. The
agreement is an extension of the great collaboration between our two companies
for PrecisionBiotics Alflorex®, which we launched in 2019, and demonstrates the
value of Navamedic’s local competence and insight in important disease areas and
consumer needs” says Kathrine Gamborg Andreassen, CEO in Navamedic ASA.

The special 1714-Serenitas® live culture in Zenflore® was discovered and
developed in partnership with scientists and clinicians from one of the world’s
leading centres of research on the microbiome and the gut-brain axis, the APC
Microbiome Institute at University College Cork, Ireland. Clinical studies have
demonstrated that Bifidobacterium longum 1714 improves the ability to handle
stressful situations, supports mental performance and combat mental fatigue.
Zenflore® also contains selected Vitamin Bs which contributes to the reduction
of fatigue and to sustain normal psychological ability.

Kathrine Gamborg Andreassen continues: “Navamedic focuses on products within
specialty pharma, medical nutrition and consumer health. Zenflore® strengthens
our position within consumer healthcare wherein we see a great potential for
development of products and categories - like stress and mental health in this
case. The agreement has a term of eight years with automatic renewal and
strengthens our position in the entire Nordic region, which is our most
important home market.”

Steve Howson, Head of B2C at Novozymes One Health commented: “We are delighted
to have reached agreement with our colleagues at Navamedic to launch Zenflore®
in the Nordic region. We already have a strong and successful partnership built
on the launch of Alflorex® in Norway, Denmark and Netherlands over the last few
years. We look forward to working with the Navamedic team to bring Zenflore® to
consumers across the region.”

PrecisionBiotics Group has for more than 20 years developed products based upon
living bacterial cultures (probiotics) in collaboration with scientists and
clinicians at the APC Microbiome Institute. Commercialised products are
clinically proven in Europe and USA. PrecisionBiotics Group was acquired by the
Danish company NovoZymes A/S in 2020.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47 917 62 842

E-mail: lars.hjarrand@navamedic.com

About Navamedic

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please visit
www.navamedic.com

About Novozymes

Novozymes is the world leader in biological solutions. Together with customers,
partners and the global community, we find biological answers to preserve the
planet’s resources and help build better lives. As the world’s largest provider
of enzyme and microbial technologies, our bioinnovation enables increased health
and nutritional benefits, higher agricultural yields, improved washing, energy
-efficient production, renewable fuel and many other benefits that we rely on
today and in the future. We call it Rethink Tomorrow. www.novozymes.com

Kilde

[Asker]

Navamedic skal lindre stress – inngår lang avtale

Toppsjef Kathrine Gamborg Andreassen ser et stort potensial.

Navamedic skal lindre stress – inngår lang avtale | Finansavisen

[TekBot]

Navamedic ASA: Annual report 2020

Oslo, 30 April 2021 - Navamedic ASA (OSE: NAVA) publishes its annual report for
2020. The report is attached and available on navamedic.com/investors.

…

Vis børsmeldingen

Highlights for 2020:

· Navamedic has made strategically important investments in its organization
and platform, including strengthening its presence and positioning in the Dutch
market and the launch of the company’s patient support program. These
investments will be key as Navamedic embark 2021 and continue to launch new
products and continue to grow its existing portfolio.
· In full-year 2020, Navamedic’s revenues increased by 11.2% to NOK 209.9 (NOK
188.8 million) with an EBITDA of negative NOK 1.3 million (negative NOK 6.5
million) driven by both new product launches and investments in further growth
initiatives.
· Gross margin improved to 33.5% (30.5%), partly due to favourable revenues
mix, reduced CoGS and other changes.
· Strengthened the company’s portfolio and offering across product categories.
In 2020, Navamedic strengthened its hospital and prescription drug offering
through the acquisition of Nordic marketing authorizations for a large hospital
antibiotics portfolio.
· The company expanded its consumer health offering by entering a long-term
exclusive distribution agreement for ThermaCare® in the Nordics and the
Netherlands. Alflorex® launched in Denmark, Iceland and the Netherlands during
the year, and continued growth in Norway.
· Continued strong performance for Mysimba®, accelerated by improved
reimbursement in Norway and Navamedic’s patient support program.
· Navamedic completed a private placement including a subsequent offering to
raise a total of NOK 52.4 in order to fund growth initiatives as well as general
corporate purposes.

“In 2020, we have continued the implementation of our growth strategy. We have
built on our solid foundation and strengthened our existing business by
leveraging and investing in our highly scalable market access platform. We have
focused strongly on launches of new products and will launch new products in at
least one country in each launch window going forward. We have increased value
through acquisitions of products and brands. In short, we have continued our
journey of building a leading Nordic pharma company, targeting growth in
Northern Europe,” says Kathrine Gamborg Andreassen, Chief Executive Officer of
Navamedic ASA.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47 917 62 842

E-mail: lars.hjarrand@navamedic.com

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please
visit www.navamedic.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

Navamedic ASA: Invitation to 2021 first quarter presentation

Navamedic ASA invites you to a presentation of the 2021 first quarter on
Tuesday May 11[th] at 08.30 CET. Due to the covid-19 situation the presentation
will only be held as a webcast. Participants can view the webcast on the
…

Vis børsmeldingen

Navamedic web site at www.navamedic.com/investors/financial-results under
‘2021’. Representatives from the Company will be: CEO Kathrine Gamborg
Andreassen and CFO Lars Hjarrand. For further information, please contact: Lars
Hjarrand. Mobile: +47 917 62 842 E-mail: lars.hjarrand@navamedic.com.

Kilde

[TekBot]

Navamedic ASA: Icepharma new distributor of antibiotics to the Icelandic market

Oslo 7 May 2021 - Navamedic ASA (“Navamedic”, OSE: NAVA) announces it has signed
an agreement with Icepharma for distribution of the antibiotics products to the
Icelandic market.
…

Vis børsmeldingen

As announced on 4 August 2020, Navamedic completed the acquisition of marketing
authorisations in the Nordics for a portfolio of antibiotics products. The
antibiotics in the portfolio, now fully onboarded on Navamedic’s platform, are
designed to be given intravenously to patients and are in regular use in
hospitals in all the Nordic countries.

In accordance with the plan to roll out antibiotics in the Nordic region,
Navamedic has signed an agreement with Icepharma for distribution of the
antibiotics products to the Icelandic market.

“The addition of the antibiotics portfolio marked an important milestone for
Navamedic and our expanding hospital and prescription drug offering. We are
pleased to welcome Icepharma to join us in securing steady supply of these
important products to Nordic hospitals,” says Kathrine Gamborg Andreassen, CEO
of Navamedic.

The antibiotics in the portfolio are designed to be given intravenously to
patients and are currently in regular use in hospitals in all the Nordic
countries with an annual turnover of approximately NOK 25 million. This
portfolio will strengthen Navamedic´s hospital offering with an important
product range. This is an important step in Navamedic´s growth strategy.

Navamedic has recruited Janne Folmoe to the company’s Specialty Pharma
commercial team. Folmoe comes with extensive experience from the ACS Dobfar
portfolio with focus on tender management, and previous commercial positions in
the pharma industry in companies such as Bayer and Mylan. Folmoe will play a key
role in the commercial operation with regards to the antibiotics portfolio.

For more information, please contact:
Kathrine Gamborg Andreassen, CEO of Navamedic ASA
kathrine@navamedic.com

Alexander Lidmejer, Commercial Director Specialty Pharma at Navamedic ASA
+46 70 257 99 71
alexander.lidmejer@navamedic.com

About Navamedic

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please visit
www.navamedic.com

Kilde

[TekBot]

Navamedic ASA: Resultater for første kvartal 2021

Oslo, 11. mai 2021 - Navamedic ASA (OSE: NAVA) økte driftsinntektene med 5.4% i
første kvartal 2021 sammenlignet med samme kvartal i fjor. Selskapet rapporterte
driftsinntekter på NOK 58.6 millioner i første kvartal i 2021, med en EBITDA på
…

Vis børsmeldingen

NOK 2.6 millioner, drevet av både nye produktlanseringer, vekst i underliggende
portefølje og forbedret sammensetning av produktinntekter. Selskapet gjentar sin
mellomlange til langsiktige ambisjon om å bli et selskap med NOK 500 millioner i
omsetning.

• Vi fortsatte å levere vekst i vår underliggende portefølje i første kvartal

2021. Den raske veksten til specialty pharma-produktet Mysimba og consumer
      health-produktene Alflorex og ThermaCare er gode eksempler på Navamedics
      posisjon innen prioriterte områder som gastro, fedme og andre livsstilsrelaterte
      helseutfordringer, sier Kathrine Gamborg Andreassen, administrerende direktør i
      Navamedic ASA, og fortsetter.

• Den akselererte veksten i disse områdene kommer som et resultat av målrettede
  investeringer i plattformen vår, pasientstøtteprogrammer, lokal
  kategoriekspertise og infrastruktur for kunder og interessenter. Disse
  investeringene vil bli viktige i 2021 når vi fortsetter å akselerere vekst
  gjennom lanseringer av nye produkter og arbeider for vekst i vår eksisterende
  portefølje.

I første kvartal 2021 var selskapets driftsinntekter NOK 58.6 millioner (55.6
millioner i første kvartal 2020). Bruttomarginen var 39.6% (28.3%), og EBITDA
var NOK 2.6 millioner (0.7). Navamedic vil lansere produkter i minst ett land
hvert lanseringsvindu framover. Selskapet sikter mot 20% årlig vekst fra 2021 og
gjentar sin mellomlange- til langsiktige ambisjon om å bli et selskap med NOK
500 millioner i omsetning med en solid bruttomargin og underliggende lønnsomhet.

Navamedic avholder en webcast-presentasjon for første kvartal 2021 tirsdag 11.
mai kl 08.30. Grunnet smittevernbestemmelser knyttet til Covid-19 vil
presentasjonen kun avholdes digitalt på www.navamedic.com/investors/financial
-results. Presentasjonen vil holdes av administrerende direktør Kathrine Gamborg
Andreassen og finansdirektør Lars Hjarrand.

EBITDA og andre alternative resultatmål (APMer) er definert og avstemt med IFRS
-regnskapet som en del av APM-delen på side 22 i vedlagte presentasjon for
første kvartal 2021.

For ytterligere informasjon, vennligst kontakt:

Kathrine Gamborg Andreassen, administrerende direktør, Navamedic

Mobil: +47 951 78 680

E-post: kathrine@navamedic.com

Lars Hjarrand, finansdirektør, Navamedic

Mobil: +47 917 62 842

E-post: lars.hjarrand@navamedic.com

Navamedic ASA er et nordisk farmaselskap som leverer høykvalitetsprodukter til
sykehus og apotek. Vår ambisjon er å ivareta pasienters og forbrukeres behov
gjennom dybdekompetanse innen utvalgte kategorier, samt inngående kunnskap om
lokale forhold i hvert marked. Navamedic er til stede i de nordiske landene,
Baltikum og Benelux, og har salgsrepresentasjon i Storbritannia og Hellas.
Navamedic har hovedkontor i Oslo og er notert på Oslo Børs (ticker: NAVA). For
mer informasjon, vennligst besøk www.navamedic.com.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

Navamedic ASA: Q1 2021 financial

Oslo, 11 May 2021 - Navamedic ASA (OSE: NAVA) grew revenues by 5.4% in the first
quarter of 2021 compared to the same quarter last year. The company reported
revenues of NOK 58.6 million in the first quarter of 2021 with an EBITDA of NOK
…

Vis børsmeldingen

2.6 million, driven by both new products, underlying growth and an improved
revenue mix. The company reiterates its mid- to long-term ambition of building a
NOK 500 million company.

"In the first quarter of 2021, we continued to deliver growth in our underlying
portfolio. The rapid growth of specialty pharma product Mysimba and the consumer
health products Alflorex and ThermaCare stand out as valued proofpoints of
Navamedic’s position in prioritized areas such as gastro, obesity and other
lifestyle related issues, says Kathrine Gamborg Andreassen, Chief Executive
Officer of Navamedic ASA, and continues.

“The accelerated growth in these areas comes as a result of targeted investments
in our platform, patient support programs, local category expertise and customer
and stakeholder infrastructure. These investments will be key in 2021 as we
continue to accelerate growth through launch of new products and push for growth
in our existing portfolio.”

Revenues in the first quarter of 2021 were NOK 58.6 million (55.6 million in the
first quarter of 2020). The gross margin was 39.6% (28.3%), while the EBITDA was
NOK 2.6 million (0.7). Navamedic will launch products in at least one country in
each launch window going forward. The company targets 20% annual growth from
2021 and reiterates its mid- to long-term ambition of building a NOK 500 million
company with strong gross margins and underlying profitability.

Navamedic is hosting a webcast presentation of the first quarter 2021 financial
results, Tuesday 11 May at 08.30 CET. Due to the Covid-19 situation, the
presentation will only be held as a live webcast, on
www.navamedic.com/investors/financial-results. Representatives from Navamedic
will be CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand.

EBITDA and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section of the
attached first quarter 2021 presentation on slide 22.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47 917 62 842

E-mail: lars.hjarrand@navamedic.com

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please
visit www.navamedic.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

Navamedic ASA: Notice of Annual General Meeting

The annual general meeting of Navamedic ASA (OSE: NAVA) will be held on
Thursday, June 3rd 2021 at 13:00 (CET) in the Navamedic offices in Henrik Ibsens
gate 90 (3rd floor), 0255 Oslo. The Notice of the Annual General Meeting is
…

Vis børsmeldingen

attached. Due to the restrictions caused by Covid-19 and advice from the
Norwegian authorities in connection therewith, all shareholders are encouraged
to exercise their shareholder rights without physical attendance at the General
Meeting. The Notice is posted electronically or by mail to all shareholders and
is available on the company’s website www.navamedic.com.

For further information, please contact:

Kathrine G. Andreassen, CEO, Navamedic, Mobile: +47 951 78 680 E-mail:
kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic, Mobile: +47 917 62 842 E-mail:
lars.hjarrand@navamedic.com

Kilde

[Quadruple]

"Navamedics driftsinntekter var 58,6 millioner kroner i første kvartal 2021 (55,6), mens ebitda utgjorde 2,6 millioner kroner (0,7).

Selskapet målsetter fortsatt en årlig vekst på 20 prosent fra 2021 med en mellomlag til langsiktig ambisjon om å bygge et selskap med en omsetning på 500 millioner kroner med en bruttomargin på 40 prosent og en ebitda-margin på 15 prosent."

Det betyr at det ligger an til godt over 200 mill. i omsetning 2021, og med stadig økende EBITDA.
Børsverdien er 377 mill, som er 1,8 ganger omsetningen.

[TekBot]

Obesity patient support program launched in Norway

Today Navamedic launches MyControl Support in Norway, a free-of-charge patient
support program in collaboration with Observia, following a successful launch in
Sweden. A new patient engagement & support program targeted towards people with
…

Vis børsmeldingen

clinical obesity. Via a brand-new online platform, the program aims to aid and
inform patients with obesity.

Navamedic, a Nordic pharma company, specialized in the field of obesity and
Observia, French e-health company specialized in patient engagement and support
solutions are proud to further provide support for patients in great need.
“Launching a platform like this is by far one of the most ambitious and
innovative initiatives we have offered the health care system. This is
continuing our efforts in attempting to highlight the complexity surrounding
this disease and offering both health care professionals and patients a
treatment option complementing and strengthening a regular treatment protocol.”
says Kathrine Gamborg Andreassen, CEO of Navamedic.

A 16-week empowerment program

Patients embark on a 16-week program, comprising lifestyle recommendations and
doctor- and patient-validated information via SMS. Participants also receive
articles on topics such as the causes, risks and benefits of long-term weight
loss as well as treatment option information.

In addition, patients are invited to take on daily challenges (going to bed
early, practicing physical activity, eating healthy) that instil healthy habits
and to progress across 10 levels of challenge. Any patient suffering from
obesity can enrol in the program.

The design and the interface of the platform have been conceived by Navamedic
and Observia to encourage patients every day and engage them to play an active
role in the management of their health.

Launch in Norway follows successful pilot in Sweden

The patient support program was first launched in Sweden in October 2020. After
first promising results, the decision was taken to further deploy the program in
Norway, where 23.1% of the population suffers from obesity.

Obesity is linked to increased incidence of many chronic diseases (type 2
diabetes, CVD, respiratory complications, etc.) which lead to increased
morbidity. In the past few decades, greater awareness around obesity and its
consequences and burden have fostered the creation of dedicated support actions
and prevention.

MyControl Support is one of them and aims to help patients improve their quality
of life.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO
kga@navamedic.com

Morgane Freudiger Marketing & Communication Director, Observia
morgane.freudiger@observia-group.com

About Navamedic
Navamedic ASA is a Nordic pharma company and a reliable supplier of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
medical needs of patients and consumers by leveraging its highly scalable market
access platform, leading category competence and local knowledge.

Navamedic is present in all the Nordic countries, the Baltics and Benelux, with
sales representation in the UK and Greece. Navamedic is headquartered in Oslo,
Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more
information, please visit www.navamedic.com

About Observia
At Observia, we are a passionate pioneer healthTech company committed to help
drive the healthcare ®evolution and improve patients’ lives. We seamlessly
design, configure and deploy multi-channel patient engagement & support
solutions, driven by AI and grounded in behavioral science, that enhance patient
engagement and deliver measurable behavioral and clinical results.

We work with all the main healthcare stakeholders that have at heart to build
patient-centered initiatives that improve patients and carers’ lives and ease
healthcare professional daily workload: industrials (Pharma, Biotech, MedTech),
healthcare facilities, HCPs, patients’ organizations and payers. Based in Paris
since 2011 and present in China since 2018, Observia’s solutions are deployed
across 20 countries and more than 40 medical specialities.

Kilde

[TekBot]

Navamedic ASA: Launch of new products strengthen the category of Medical Nutrition

Oslo June 1[th], 2021 - Navamedic ASA (“Navamedic”, OSE: NAVA) announces the
launch of new products in the Nordics.

…

Vis børsmeldingen

Medical Nutrition is a strategically important area for Navamedic and to further
strengthen our presence, we have now launched three new products in this
category. The first to be launched is Glycosade Lemon for the dietary treatment
of Glycogen Storage Disease (GSD), an inborn error of metabolism. The other two,
K.Flo and K.Yo, are both used for the dietary management of drug-resistant
epilepsy or other conditions for which a ketogenic diet is indicated.

“We are proud to announce that the addition of these new products to the
existing portfolio will enhance our strategy of delivering a complete range of
products for patients with metabolic disorders or drug-resistant epilepsy. This
will give patients who are on a very strict dietary regimens an increased choice
of options which will make the adherence to dietary treatment easier.” says
Fredrik Karlsson, KAM Medical Nutrition of Navamedic.

Navamedic has products that combine the best of cutting-edge research with the
lifestyle demands of modern living. By launching new products to meet complex
dietary treatments, Navamedic will continue to offer new product lines
throughout the year, always with the patient at the core.

The Medical Nutrition business segment is based on the sale of products for the
treatment of inborn errors of metabolism (IEM). Within Medical Nutrition,
Navamedic is a Nordic distributor of products purchased from the UK based
company Vitaflo International ltd, a subsidiary of Nestlé. Navamedic’s vendor
Vitaflo has more than 30 years of experience in producing specialist nutritional
products for Inborn Errors of Metabolism (IEM).

For more information, please contact:
Alexander Lidmejer, Commercial Director Specialty Pharma at Navamedic ASA, +46
70 257 99 71 alexander.lidmejer@navamedic.com

About Navamedic
Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please visit
www.navamedic.com

Kilde

[TekBot]

Navamedic ASA: Minutes of Annual General Meeting

Oslo, 3 June 2021: The Annual General Meeting of Navamedic ASA was held today at 13:00 CEST. All items on the agenda were resolved in accordance with the board of directors’ proposals and the nomination committee’s recommendations.

A copy of the minutes from the Annual General Meeting are attached to this notice and will also be made available at the Company’s webpage www.navamedic.com.
…

Vis børsmeldingen

For further information, please contact:

Kathrine G. Andreassen, CEO, Navamedic,
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic,
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com

This information is subject to the disclosure requirements pursuant to the Continuing Obligations for Issuers of Shares in accordance with Oslo Rule Book II - Issuer Rules.

Kilde

[Quadruple]

17.6.2021, 12:21 · TDN Finans Delayed

NAVA: VUNNET ANTIBIOTIKA-ANBUD HOS NORSKE SYKEHUS

Oslo (TDN Direkt): Navamedic har vunnet anbud for visse antibiotikatyper for det norske sykehusmarkedet.

Det skriver selskapet i en melding torsdag.

Ifølge meldingen gjelder anbudsseieren for hele det norske markedet for fire store antibiotikatyper for perioden fra februar 2022 til februar 2024.

“Dette anbudet vil sikre en betydelig del av det anslåtte salgsvolumet for Navamedic sin antibiotikaporteføljen gjennom 2023”, heter det i meldingen.